These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18754001)

  • 1. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.
    Perini JA; Struchiner CJ; Silva-Assunção E; Santana IS; Rangel F; Ojopi EB; Dias-Neto E; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Dec; 84(6):722-8. PubMed ID: 18754001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
    Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
    J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
    Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
    Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
    Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
    Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
    Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
    Schwartz JB; Kane L; Moore K; Wu AH
    J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
    Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
    Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement.
    Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V
    Thromb Haemost; 2006 May; 95(5):782-7. PubMed ID: 16676068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study.
    Zambon CF; Pengo V; Padrini R; Basso D; Schiavon S; Fogar P; Nisi A; Frigo AC; Moz S; Pelloso M; Plebani M
    Pharmacogenomics; 2011 Jan; 12(1):15-25. PubMed ID: 21174619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.
    Wen MS; Lee M; Chen JJ; Chuang HP; Lu LS; Chen CH; Lee TH; Kuo CT; Sun FM; Chang YJ; Kuan PL; Chen YF; Charng MJ; Ray CY; Wu JY; Chen YT
    Clin Pharmacol Ther; 2008 Jul; 84(1):83-9. PubMed ID: 18183038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of warfarin pharmacogenetic testing in clinical practice.
    Tan GM; Wu E; Lam YY; Yan BP
    Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.